



PISA-School of Clinical and Experimental Psychiatry
Institute for Improving Neuroscientific Knowledge



Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders

Psicopatologia del Neurosviluppo negli adulti: Disturbi depressivi, bipolari, psicotici e correlati all'uso di sostanze



July, 8-9 2019

Pisa, Italy, EU

**Hotel Galilei
Via Darsena, 1
56121 - PISA**

**PROGRAMME
Final Draft**

Bilingual event



Under the patronage of

University of Pisa
Department of Experimental and Clinical Medicine (requested)



Santa Chiara University Hospital (AOUP) (requested)



PISA-School of Clinical and Experimental Psychiatry
Institute for Improving Neuroscientific Knowledge

PISA-School of Clinical and Experimental Psychiatry
Institute for improving neuroscientific knowledge
Pisa

In collaboration with



World Association on Dual Disorder (WADD)
Italian Scientific Committee



Italian Society of Addiction Medicine (SITD)
Sezione Toscana



Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS)

Scientific Committee

Icro Maremmani (Pisa, Italy)
Giulio Perugi (Pisa, Italy)

Department of Experimental and Clinical
Medicine
2nd Psychiatric Unit
Santa Chiara University Hospital
Via Roma 67, 56100 PISA
UNIVERSITY OF PISA, Italy

Organizing Committee

Cristina Toni (Pisa, Italy)
Matteo Pacini (Pisa, Italy)



Institute of Behavioural Sciences
Via di Pratale 3, 56127 PISA

e-mail: info@iscdelisio.org

To register to the conference, please visit <http://iscdelisio.org/eventi-e-corsi/>



PROGRAMME

MONDAY, JULY 8, 2019

	<i>Chair: Icro Maremmani (Pisa, Italy) - Giulio Perugi (Pisa, Italy)</i>
14:00	Giulio PERUGI (Pisa, Italy) - ADHD, traiettorie del Neurosviluppo e Disturbi Mentali dell'Adulto
14:40	Gabriele MASI (Pisa, Italy) - Diagnosi e trattamento farmacologico nei disturbi dell'umore nei pazienti con disabilità intellettiva
15:20	Roberto KELLER (Torino, Italy) - Titolo/Management of Adult ASD
16:00	COFFEE BREAK
16:20	Alessandro ZUDDAS (Cagliari, Italy) - Diagnosi e trattamento farmacologico nei disturbi dell'umore nei pazienti con disturbi dello spettro autistico (ASD)
17:00	Marco O. BERTELLI (Firenze, Italy) - Terapie farmacologiche dei disturbi dell'umore e del comportamento nelle disabilità intellettive
17:40	Matteo GASTALDI (Pavia, Italy) - Presentazione psichiatriche delle encefaliti autoimmuni
18:20	DISCUSSION
18:40	Giulio PERUGI (Pisa, Italy) - Guida pratica all'impiego dei sali di litio
19:00	CLOSING





TUESDAY, JULY 9, 2019

	<i>Chair: Icro Maremmani (Pisa, Italy), Giulio Perugi (Pisa, Italy)</i>
9:00	Kostas FOUNTOULAKIS (Thessaloniki, Greece) - Staging schizophrenia on the basis of clinical picture alone: A new conceptual model based on an international multi-center study
9:40	Alessandro SERRETTI (Bologna, Italy) - Nuove prospettive nel trattamento della depressione
10:20	Giulio PERUGI (Pisa, Italy) - Novità in tema di farmaci antipsicotici. Efficacia e tollerabilità
11:00	COFFEE BREAK
	<i>Chair: Icro Maremmani (Pisa, Italy), Francesco Lamanna (Pisa, Italy)</i>
11:20	Maurice DEMATTEIS (Grenoble, France) - Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
12:00	Lorenzo SOMAINI (Biella, Italy) - La genetica del Disturbo da Uso di Oppiacei
12:40	DISCUSSIONE
13:00	PAUSA PRANZO
14:00	POSTERSESSION
15:00	Gilberto GERRA (UNODC, Vienna) - Cure genitoriali durante l'infanzia e disturbi da uso di sostanze nell'adulto
15:40	Marta TORRENS (Barcelona, Spain) - Opioid and depression
16:20	Roberto SARLO (Lucca, Italy) - Doppia Diagnosi: verso un'Unica organizzazione per risposte cliniche appropriate
16:40	Angelo G.I. MAREMMANI (Viareggio, Italy) - Verso una psicopatologia specifica del Disturbo da Uso di Sostanze
17:00	Guido INTASCHI (Viareggio, Italy) - La collaborazione tra Servizi Dipendenze, privato sociale e gruppi di auto-aiuto nei percorsi socio-assistenziali dell'area dipendenze
17:20-	Matteo PACINI (Pisa, Italy) - Correlati diagnostici e implicazioni terapeutiche della dipendenza da sedativi del SNC (alcol e BDZ), come mono - o poliabuso
17:40	Francesco LAMANNA (Pisa, Italy) - Doppia Diagnosi o Disturbo Duale, Uovo o Gallina: l'esperienza del Ser.D. di Pisa
18:00	DISCUSSIONE
18:40	LUCA ROVAI "Giovani Ricercatori" AWARD - Presentazione del poster premiato
19:00	QUESTIONARIO ECM



Faculty

Marco O. BERTELLI	Fondazione San Sebastiano, Misericordia di Firenze, Firenze, Italy, EU
Maurice DEMATTEIS	Department of Addictions, University Hospital of Grenoble, Joseph Fourier University, Grenoble, France, EU
Kostas FOUNTOULAKIS	Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece, EU
Matteo GASTALDI	Fondazione Istituto Neurologico Nazionale C. Mondino IRCCS Pavia, Italy, EU
Gilberto GERRA	United Nations Office on Drugs and Crime, Vienna (UNODC)
Guido INTASCHI	Dipartimento di Psichiatria e Dipendenze, Azienda ASL Toscana Nord-Ovest, Versilia, Italy, EU
Roberto KELLER	Centro di Salute Mentale, ASL TO 2, Regione Piemonte, Torino, Italy, EU
Francesco LAMANNA	Dipartimento di Psichiatria e Dipendenze, Azienda ASL Toscana Nord-Ovest, Pisa, ITALY, EU
Angelo G.I. MAREMMANI	Dipartimento di Psichiatria e Dipendenze, Azienda ASL Toscana Nord-Ovest, Versilia, Italy, EU
Icro MAREMMANI	Azienda Ospedaliero Universitaria Pisana, Università di Pisa, Italy, EU
Gabriele MASI	Fondazione IRCCS "Stella Maris", Calambrone, Pisa, Italy, EU
Matteo PACINI	Istituto di Scienze del Comportamento 'G. De Lisio', Pisa, Italy, EU
Giulio PERUGI	Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy, EU
Roberto SARLO	Dipartimento di Psichiatria e Dipendenze, Azienda ASL Toscana Nord-Ovest, Lucca, Italy, EU
Alessandro SERRETTI	Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Italy, EU
Lorenzo SOMAINI	SerT, Azienda Sanitaria Locale Biella, Italy, EU
Marta TORRENS	IMIM Hospital del Mar Medical Research Institute, Autonomous University of Barcelona, Spain, EU
Alessandro ZUDDAS	Dipartimento di Scienze Biomediche, Sez. Neuroscienze e Farmacologia Clinica, Università di Cagliari, Italy, EU



PISA-School of Clinical and Experimental Psychiatry
Institute for Improving Neuroscience Knowledge

Pisa, Italy, July 8-9, 2019



PISA-School of Clinical and Experimental Psychiatry
Institute for Improving Neuroscience Knowledge



To register to the conference, please visit
<http://iscdelisio.org/eventi-e-corsi/>



*PISA-School of Clinical and Experimental Psychiatry
Institute for Improving Neuroscientific Knowledge*

The PISA-School of Experimental and Clinical Psychiatry (PISA-School of Psychiatry) was founded in November 2017 by a group of ex-students of the School of Specialization in Psychiatry at the University of Pisa. It wants to maintain over time that communion of clear and professional intent that the students have experienced during their specialisation course. The PISA-School of Psychiatry aims to be a meeting point for former students who want to continue to maintain close contact with each other and with the current and past teachers of the school. For this reason, they will organise refresher courses and specific congresses to maintain their continuing education in psychiatry at the highest level.

The PISA-School of Experimental and Clinical Psychiatry is a no-profit organisation that shall remain independent of political parties and any government. The objects of The Association are to promote, in the EU and elsewhere, the effective treatment of psychiatric patients, affective disorder and substance use disorder patients in particular, but without prejudice to the generality of the following:

- To promote at a national and international level the diffusion, the development and the progress of studies and research in the field of behavioural neurosciences, and the application of this neuroscientific knowledge to social aims;
- to promote the development and acceptance of treatment with psychiatric medications and other prescribed medications, including long-term prescribing and the utilisation of physical treatment
- to enhance the provision and quality of services to psychiatric patients and their families;
- to promote a better understanding of psychiatric treatment by the general public and its elected representatives and officials;
- to promote collaborative research and to provide a European research centre;
- to work with other Associations to promote support for psychiatric treatment world-wide;
- to promote goodwill and co-operation among the staff of psychiatric services and other medical treatment services in Europe and elsewhere,

so in pursuit of any of the preceding objects, to obtain financial support from government agencies, philanthropic organisations, corporations and any other sources, public or private.

